Pharmacokinetic/Pharmacokinetic and Safety Studies of SHR4640 in Subjects With Moderate Renal Insufficiency and Healthy Subjects
Study Details
Study Description
Brief Summary
This study aimed to evaluate the pharmacokinetics, pharmacodynamics, and safety of SHR4640 tablets in subjects with moderate renal insufficiency and healthy subjects, and to explore the relationship between renal function (e.g., eGFR) and SHR4640 pharmacokinetic and pharmacodynamic parameters.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Treatment group A in moderately renal insufficiency subjects
|
Drug: SHR4640
SHR4640 single-dose
|
| Experimental: Treatment group B in healthy subjects
|
Drug: SHR4640
SHR4640 single-dose
|
Outcome Measures
Primary Outcome Measures
- PK parameters of SHR4640: Cmax [0 hour to 72 hour after administration]
- PK parameters of SHR4640: AUC0-t [0 hour to 72 hour after administration]
- PK parameters of SHR4640: AUC0-inf [0 hour to 72 hour after administration]
Secondary Outcome Measures
- PK parameters of SHR4640: Tmax [0 hour to 72 hour after administration]
- PK parameters of SHR4640: t1/2 [0 hour to 72 hour after administration]
- PK parameters of SHR4640: CL/F [0 hour to 72 hour after administration]
- PK parameters of SHR4640: Vz/F [0 hour to 72 hour after administration]
- Amount of SHR4640 excreted in urine (Ae0-72h) [0 hour to 72 hour after administration]
- Serum uric acid concentration [0 hour to 72 hour after administration]
- Amount of uric acid excreted in urine [0 hour to 72 hour after administration]
- Adverse events [from ICF signing date to approximate day 8]
Eligibility Criteria
Criteria
Inclusion Criteria:
Moderate renal impaired subjects:
-
Able and willing to provide a written informed consent.
-
18 years to 65 years (inclusive).
-
Body mass index should be between 18 and 35 kg/m2 (inclusive).
-
eGFR should be between 30 and 59 mL/min/1.73 m2 (inclusive).
-
The renal function status is stable, and the results of two eGFR tests during the screening period (at least 3 days apart, but within 14 days) should be within ±25%.
-
If subjects with underlying diseases required drug treatment, the dose needs to be kept stable during study.
Healthy subjects:
-
Able and willing to provide a written informed consent.
-
18 years to 65 years (inclusive).
-
Body mass index should be between 18 and 35 kg/m2 (inclusive).
-
eGFR should be ≥ 90 and < 130 mL/min/1.73 m2.
-
The renal function status is stable, and the results of two eGFR tests during the screening period (at least 3 days apart, but within 14 days) should be within ±25%.
Exclusion Criteria:
All subjects:
-
Pregnant or nursing women.
-
No birth control until one week after SHR4640 administration.
-
Average daily alcohol consume more than 14g for female or more than 28g for male within 1 month before screening, or baseline alcohol screening is positive.
-
Smokers (average daily smoking of 10 cigarettes or more in the 3 months before screening).
-
Subject with a history of substance abuse and drug abuse.
-
The investigators determined that other conditions were inappropriate for participation in this clinical trial.
-
2 weeks before SHR4640 administration sUA level ≥480 μmol/L.
-
Alanine aminotransferase and/or aspartate aminotransferase>2×ULN, alkaline phosphatase (ALP)>2.5×ULN.
-
Positive result for hepatitis B surface antigen.
-
Positive result for human immunodeficiency virus (HIV), hepatitis C virus antibody or syphilis antibody.
-
White blood cell < 3.0×109/L, and/or hemoglobin <80 g/L, and/or platelet <80×109/L;
-
12-lead electrocardiogram (ECG) showed abnormal and clinically significant.
-
History of hypersensitivity to SHR4640 or its analogues.
-
History or suspected crystals or stones in the urinary system during the screening period of B-ultrasound.
-
History of been diagnosed with acute kidney injury in the past or screening period.
-
Cardiovascular, neuropsychiatric, respiratory, digestive tract, endocrine and other systemic diseases within 1 year before screening, which were judged to be serious by the investigators.
-
Have grade III or IV congestive heart failure (New York Heart Association classification) or myocardial infarction, unstable angina, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage or transient ischemic attack within 1 year of screening, and other cardiovascular and cerebrovascular events leading to hospitalization.
-
History of active peptic ulcer within 1 year before screening, previous history of active gastrointestinal bleeding, gastrointestinal perforation, history of inflammatory bowel disease, or active peptic ulcer at screening.
-
Have a malignant tumor, or have a history of malignant tumor within 5 years before screening.
-
SBP≥180 mmHg and/or DBP ≥110 mmHg.
-
Had undergone major surgery within 3 months prior to screening, or have not recovered from surgery, or plan major surgery during the study.
-
Received the last dose of a study drug (or treatment with a medical device) within 3 months or 5 T1/2 (whichever is longer) of the screening or are currently participating in another study of a study drug (or medical device).
-
Blood donation within 1 month before screening; Or patients with trauma or major surgical procedures who donated blood or lost blood ≥400 mL in the 3 months prior to screening.
-
Has unsuitable venous for blood sampling.
-
Use of any of the following, unless agreed as nonclinically relevant by the
Investigator and the Sponsor:
- Use of any over the-counter, nutraceuticals, or prescription medications that might interfere with the absorption, distribution, metabolism, or excretion of SHR4640 (proton-pump inhibitor, fluconazole, indomethacin, ranitidine, flurbiprofen, probenecid, aprepitant, etc.) within 2 weeks of screening; 2) Unstable dosage of urate-lowering drugs within 6 weeks of Day 1; 3) Diuretics within 2 weeks of Day 1; 4) Aspirin in excess of 100 mg daily or unstable dose within the 2 weeks of Day 1; 5) Unstable dosage of antihypertensive, lipid-lowering and hypoglycemic drugs within 2 weeks of Day 1; 6) Have received or been exposed to other live vaccines or live attenuated vaccines within 3 months prior to Day 1, or who plan to receive live vaccines or live attenuated vaccines during the study.
- Consumes grapefruit and/or poppy seed within 48 hours before SHR4640 administration.
Moderate renal impaired subjects:
- History of kidney transplantation. 28. Renal dialysis required during the study. 29. Urinary incontinence or anuria (eg< 100 mL/d). 30. Taken prescription drugs, over-the-counter drugs, herbal medicines or food supplements other than drugs for the treatment of renal insufficiency and other concomitant diseases within 2 weeks before Day
Healthy subjects:
-
History of chronic kidney disease or history of kidney transplantation, or physical examination and laboratory tests at screening, indicating the presence or possibility of renal impairment.
-
Taken any prescription drugs, over-the-counter drugs, Chinese herbal medicines or food supplements within 2 weeks prior to taking the study drug.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Jiangsu HengRui Medicine Co., Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- SHR4640-111